Targeted Therapy for Idiopathic Inflammatory Myopathy

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Idiopathic inflammatory myopathies (IIM) are autoimmune disorders causing chronic muscle inflammation and extramuscular issues.
• Many patients have refractory or relapsing disease despite standard immunosuppression.
• Novel targeted treatments are needed, with advances identifying new therapeutic targets.

Purpose of the Study:

• To review current evidence on targeted therapies for idiopathic inflammatory myopathies (IIM).
• To synthesize data on the efficacy and safety of various targeted treatments.
• To highlight recent advances and future directions in IIM management.

Main Methods:

• Systematic literature search of PubMed, Cochrane Library, and Google Scholar up to September 2025.
• Inclusion of randomized controlled trials, observational studies, meta-analyses, and case reports.
• Synthesis of evidence on efficacy, safety, and outcomes across IIM subtypes.

Main Results:

• Targeted therapies are revolutionizing IIM management, with B-cell therapies like rituximab being a cornerstone for refractory cases.
• Janus kinase (JAK) inhibitors show efficacy for cutaneous and lung manifestations.
• Emerging therapies include Fc receptor antagonism and advanced cellular therapies like CAR-T-cell therapy, demonstrating sustained remission in severe cases.

Conclusions:

• The landscape of targeted therapies for IIM is rapidly evolving, allowing for more precise and effective patient management.
• These strategies offer significant promise for improving outcomes in patients with refractory IIM.
• Future research should prioritize biomarker discovery for treatment selection, larger clinical trials, and long-term safety monitoring.